Purvalanol B

Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor CDK, with IC50s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. Purvalanol B shows selectivity for CDK over a range of other protein kinases (IC50>1000 nM) . Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum[1][1].

Product Specifications

CAS Number

[212844-54-7]

Product Name Alternative

NG 95

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CDK; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Purvalanol-B.html

Purity

97.0

Solubility

DMSO : ≥ 40 mg/mL

Smiles

O=C(O)C1=CC=C(NC2=C3N=CN(C(C)C)C3=NC(N[C@@H](CO)C(C)C)=N2)C=C1Cl

Molecular Formula

C20H25ClN6O3

Molecular Weight

432.90

Precautions

H302, H315, H319, H335

References & Citations

[1]Gray NS, et, al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281 (5376) :533-8.|[2]Bullard KM, et, al. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. Malar J. 2015 Apr 8;14:147.